Synthesis of Verubecestat, a BACE1 Inhibitor for the Treatment of Alzheimer's Disease

被引：35

作者：

Thaisrivongs, David K. ^{[1
]}

Miller, Steven P. ^{[1
]}

Molinaro, Carmela ^{[1
]}

Chen, Qinghao ^{[1
]}

Song, Zhiguo J. ^{[1
]}

Tan, Lushi ^{[1
]}

Chen, Lu ^{[3
]}

Chen, Wenyong ^{[1
]}

Lekhal, Azzeddine ^{[2
]}

Pulicare, Sarah K. ^{[2
]}

Xu, Yanke ^{[2
]}

机构：

[1] Merck Res Labs, Proc Chem, POB 2000, Rahway, NJ 07065 USA

[2] Merck Res Labs, Chem Engn Res & Dev, Proc Res & Dev, POB 2000, Rahway, NJ 07065 USA

[3] WuXi AppTec Shanghai Pharmaceut Co Ltd, 288 Fute Zhong Rd, Shanghai 200131, Peoples R China

来源：

ORGANIC LETTERS | 2016年 / 18卷 / 22期

关键词：

EFFICIENT COPPER CATALYST; ARYL HALIDES; AMIDATION; AMINES;

D O I：

10.1021/acs.orglett.6b01793

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

Verubecestat is an inhibitor of beta-secretase being evaluated for the treatment of Alzheimer's disease. The first generation route relies on an amide coupling with a functionalized aniline, the preparation of which introduces synthetic inefficiencies. The second-generation route replaces this with a copper-catalyzed C-N coupling, allowing for more direct access to the target. Other features of the new route include a diastereoselective Mannich-type addition into an Ellman sulfinyl ketimine and a late-stage guanidinylation.

引用

页码：5780 / 5783

页数：4

共 50 条

[21] BACE1 as a Potential Biomarker for Alzheimer's Disease
Decourt, Boris
Sabbagh, Marwan N.
JOURNAL OF ALZHEIMERS DISEASE, 2011, 24 : 53 - 59
[22] Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs
Riqiang Yan
Translational Neurodegeneration, 5
[23] In Silico Design of BACE1 Inhibitor for Alzheimer′s Disease by Traditional Chinese Medicine
Huang, Hung-Jin
Lee, Cheng-Chun
Chen, Calvin Yu-Chian
BIOMED RESEARCH INTERNATIONAL, 2014, 2014
[24] Influence of a tripartite BACE1 inhibitor on retina in an Alzheimer's disease mouse model
Loeffler, Jana
Karich, Felix
Knels, Claudia
Valtink, Monika
Knoelker, Hans-Joachim
Funk, Richard
Schroeder, Cornelia
Knels, Lilla
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
[25] Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs
Yan, Riqiang
TRANSLATIONAL NEURODEGENERATION, 2016, 5
[26] Alzheimer disease: BACE1 inhibitor reduces β-amyloid production in humans
Crunkhorn S.
Nature Reviews Drug Discovery, 2017, 16 (1) : 18 - 18
[27] BACE1 and BACE2 enzymatic activities in Alzheimer's disease
Ahmed, Rachel R.
Holler, Christopher J.
Webb, Robin L.
Li, Feng
Beckett, Tina L.
Murphy, M. Paul
JOURNAL OF NEUROCHEMISTRY, 2010, 112 (04) : 1045 - 1053
[28] BACE1 inhibitor drugs for the treatment of Alzheimer's disease: Lessons learned, challenges to overcome, and future prospects
Ghosh, Arun K.
GLOBAL HEALTH & MEDICINE, 2024, 6 (03): : 164 - 169
[29] BACE1 structure and function in health and Alzheimer's disease
Cole, Sarah L.
Vassar, Roger
CURRENT ALZHEIMER RESEARCH, 2008, 5 (02) : 100 - 120
[30] Inhibition of BACE1 for therapeutic use in Alzheimer's disease
Luo, Xiaoyang
Yan, Riqiang
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2010, 3 (06): : 618 - 628

← 1 2 3 4 5 →